Trial Profile
Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 19 Sep 2022
Price :
$35
*
At a glance
- Drugs Fenoldopam (Primary) ; Indometacin
- Indications Acute kidney injury
- Focus Biomarker; Pharmacodynamics
- Acronyms Fenaki
- 16 Apr 2019 Planned End Date changed from 1 Dec 2019 to 1 Dec 2022.
- 16 Apr 2019 Planned primary completion date changed from 1 May 2019 to 1 May 2021.
- 16 Apr 2019 Status changed from not yet recruiting to recruiting.